Back to search
FDAFDA · Food and drugs·Recall number D-0160-2023

Triamterene and Hydrochlorothiazide Capsules, USP (37.5 mg/25 mg), Rx Only, 1000 Capsules per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC: 0527-1632-10

Published January 25, 2023 · Recall initiated: November 9, 2022

Summary

FDA records drug Class III recall D-0160-2023, published January 25, 2023 and initiated November 9, 2022. Recalling firm: Lannett Company Inc.; Status: Terminated; Reported quantity: 5,640 bottles; Lot: Lots: 20256318A (12/2022), 20256321A (12/2022), 21000238A (01/2023). Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurity/Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Lannett Company Inc.
Distributor
Nationwide USA
Lot
Lots: 20256318A (12/2022), 20256321A (12/2022), 21000238A (01/2023)
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Triamterene and Hydrochlorothiazide Capsules, USP (37.5 mg/25 mg), Rx Only, 1000 Capsules per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC: 0527-1632-10 recalled?

Yes. FDA published recall D-0160-2023 on January 25, 2023. Reported hazard: Failed Impurity/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter